Lv5
1290 积分 2022-06-08 加入
The Liver Meeting: 2025 Abstracts
1个月前
已关闭
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Once-Weekly Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
1个月前
已完结
LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis
1个月前
已完结
Repeating measurements by transient elastography in non‐alcoholic fatty liver disease patients with high liver stiffness
1个月前
已完结
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
1个月前
已完结
Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
1个月前
已完结
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
1个月前
已完结
皖公网安备34019202002308
